

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2017

	Current Quarter Ended 31.12.2017 (Unaudited) RM'000	Corresponding Quarter Ended 31.12.2016 (Unaudited) RM'000	Current Year-To-Date Ended 31.12.2017 (Unaudited) RM'000	Corresponding Year-To-Date Ended 31.12.2016 (Audited) RM'000
Revenue	103,091	14,043	303,451	40,013
Operating profit	2,698	3,163	12,953	9,208
Operating expenses	(2,549)	(1,322)	(8,832)	(9,464)
Finance expenses	(24)	(53)	(109)	(199)
Profit/(Loss) before tax	125	1,788	4,012	(455)
Income tax (expense)/credit	(16)	406	(372)	395
Profit/(Loss) after tax	109	2,194	3,640	(60)
Other comprehensive income/(expense), net of tax <i>Items that may be reclassified subsequently to profit or loss</i>				
Foreign currency translation	(73)	32	(129)	56
	(73)	32	(129)	56
Total comprehensive income/(expense)	36	2,226	3,511	(4)
Profit/(Loss) after tax attributable to owners of:				
- the Company:	109	2,203	3,474	(130)
- non-controlling interest:	-	(9)	166	70
	109	2,194	3,640	(60)
Total comprehensive income/(expense) attributable to owners of:				
- the Company:	36	2,235	3,345	(74)
- non-controlling interest:	-	(9)	166	70
	36	2,226	3,511	(4)
Earnings/(Loss) per share (sen) attributable to owners of the Company:				
- Basic	0.02	0.49	0.72	(0.03)
- Diluted	0.02	0.48	0.65	(0.03)

Note:-

The above condensed consolidated statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2016 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2017

	As At Financial Year End 31.12.2017 (Unaudited) RM'000	As At Financial Year End 31.12.2016 (Audited) RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	37,671	35,243
Product development expenditure	-	-
	<u>37,671</u>	<u>35,243</u>
Current assets		
Inventories	5,636	10,986
Trade receivables	22,669	5,987
Other receivables, deposits and prepayments	4,249	2,043
Tax refundable	1,526	1,403
Fixed and short term deposits with licensed banks	19,624	37,563
Cash and bank balances with licensed banks and other financial institution	27,776	12,990
	<u>81,480</u>	<u>70,972</u>
TOTAL ASSETS	<u>119,151</u>	<u>106,215</u>
EQUITY AND LIABILITIES		
Equity		
Share capital	48,231	47,912
Share premium	15,054	15,054
Treasury shares	(242)	(242)
Warrants Reversees	10,909	10,909
Retained profits	20,663	18,610
Revaluation reserves	13,369	13,393
Merger deficit	(8,397)	(8,397)
Currency translation reserve	(133)	(4)
Attributable to owners of the Company	<u>99,454</u>	<u>97,235</u>
Non-controlling interest	266	100
	<u>99,720</u>	<u>97,335</u>
Non-current liabilities		
Deferred taxation	898	945
Hire purchase payables	150	209
Term loans	900	1,270
	<u>1,948</u>	<u>2,424</u>
Current Liabilities		
Trade payables	14,919	1,859
Bill payable	-	2,783
Other payables and accruals	2,015	1,383
Amount owing to Directors	22	-
Hire purchase payables	59	65
Term loans	370	351
Provision for taxation	98	15
	<u>17,483</u>	<u>6,456</u>
TOTAL LIABILITIES	<u>19,431</u>	<u>8,880</u>
TOTAL EQUITY AND LIABILITIES	<u>119,151</u>	<u>106,215</u>
Net assets per share (RM) attributable to owners of the Company	<u>0.21</u>	<u>0.20</u>

Note:-

The above condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2016 and the accompanying explanatory notes attached to the interim financial statements.

The net assets per share attributable to owners of the Company is calculated based on net assets value divided by the number of ordinary shares in issue at the end of the reporting period of 481,620,347 (2016: 478,426,141) excluding treasury shares held.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2017

	Share Capital RM'000	Share Premium RM'000	Treasury Shares RM'000	Warrants Reserves RM'000	Revaluation Reserves RM'000	Merger Deficit RM'000	Currency Translation Reserve RM'000	Retained Profits RM'000	Attributable to owners of the Company RM'000	Non- Controlling Interest RM'000	Total Equity RM'000
Quarter ended 31 December 2017											
(Unaudited)											
Balance at 1 January 2017	47,912	15,054	(242)	10,909	13,393	(8,397)	(4)	18,610	97,235	100	97,335
Profit after tax for the financial year	-	-	-	-	-	-	-	3,474	3,474	166	3,640
Other comprehensive income/(expense) for the financial year, net of tax:											
- Foreign currency translation	-	-	-	-	-	-	(129)	-	(129)	-	(129)
Total comprehensive income/(expense) for the financial year	-	-	-	-	-	-	(129)	3,474	3,345	166	3,511
Issuance of shares	319	-	-	-	-	-	-	-	319	-	319
Interim dividend	-	-	-	-	-	-	-	(1,445)	(1,445)	-	(1,445)
Amortisation of revaluation reserve	-	-	-	-	(24)	-	-	24	-	-	-
Balance at 31 December 2017	48,231	15,054	(242)	10,909	13,369	(8,397)	(133)	20,663	99,454	266	99,720
Quarter ended 31 December 2016											
(Audited)											
Balance at 1 January 2016	29,814	-	(201)	-	15,650	(8,397)	(60)	16,483	53,289	30	53,319
Profit/(Loss) after tax for the financial year	-	-	-	-	-	-	-	(130)	(130)	70	(60)
Other comprehensive income/(expense) for the financial year, net of tax:											
- Foreign currency translation	-	-	-	-	-	-	56	-	56	-	56
Total comprehensive income/(expense) for the financial year	-	-	-	-	-	-	56	(130)	(74)	70	(4)
Issuance of shares	18,098	15,054	-	10,909	-	-	-	-	44,061	-	44,061
Purchase of own shares	-	-	(41)	-	-	-	-	-	(41)	-	(41)
Disposal of property, plant and equipment	-	-	-	-	(2,240)	-	-	2,240	-	-	-
Amortisation of revaluation reserve	-	-	-	-	(17)	-	-	17	-	-	-
Balance at 31 December 2016	47,912	15,054	(242)	10,909	13,393	(8,397)	(4)	18,610	97,235	100	97,335

The above condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2016 and the accompanying explanatory notes attached to

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2017

	Current Year To Date Ended 31.12.2017 (Unaudited) RM'000	Corresponding Year To Date Ended 31.12.2016 (Audited) RM'000
Cash flows from/(for) operating activities		
Profit/(Loss) before tax	4,012	(454)
Adjustments for:-		
Depreciation of property, plant and equipment	989	959
Interest expense	95	199
(Write back)/Write down of inventories	(449)	313
Inventories written off	382	174
Loss on disposal of property, plant and equipment	-	368
Interest income	(855)	(900)
Allowance for impairment loss on trade receivables	6	5
Unrealised loss/(gain) on foreign exchange	204	(55)
Operating profit before working capital changes	4,384	609
Decrease in inventories	5,418	5
(Increase)/Decrease in trade and other receivables	(18,947)	3,034
Increase/(Decrease) in trade and other payables	13,691	(2,933)
Cash from operations	4,546	715
Net tax paid	(459)	(259)
Interest paid	(97)	(199)
Net cash from operating activities	3,990	257
Cash flows (for)/from investing activities		
Interest received	855	900
Proceeds from disposal of property, plant and equipment	-	3,468
Purchase of property, plant and equipment	(3,417)	(6,636)
Net cash for investing activities	(2,562)	(2,268)
Cash flows (for)/from financing activities		
Repayment of term loans	(349)	(2,103)
(Repayment)/Drawdown of bills payable	(2,783)	2,783
Advance from/(Repayment to) Directors	22	(4)
Repayment of hire purchase obligations	(65)	(190)
Interim dividend	(1,445)	-
Purchase of own shares	-	(41)
Proceeds from issuance of shares	319	44,061
Net cash (for)/from financing activities	(4,301)	44,506
Net (decrease)/increase in cash and cash equivalents	(2,873)	42,495
Cash and cash equivalents at beginning of the financial year	50,553	8,095
Foreign exchange difference	(280)	(37)
Cash and cash equivalents at end of the financial year	47,400	50,553
Cash and cash equivalents comprise:		
Fixed and short term deposits with licensed banks	19,624	37,563
Cash and bank balances with licensed banks and other financial institution	27,776	12,990
	47,400	50,553

Note:-

The above condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2016 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)

(Incorporated in Malaysia)

NOTES TO THE INTERIM STATEMENTS FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2017

A. NOTES PURSUANT TO THE MALAYSIAN FINANCIAL REPORTING STANDARD 134 (MFRS 134): INTERIM FINANCIAL REPORTING

A1. Basis of reporting preparation

The unaudited interim financial statements have been prepared in accordance with the Malaysian Financial Reporting Standards (“MFRS”) 134: “Interim Financial Reporting” issued by the Malaysian Accounting Standards Board (“MASB”) and Chapter 9, Part K of the Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”) for the ACE Market (“ACE LR”). The unaudited interim financial statements should be read in conjunction with the audited annual financial statements of the Group for the financial year ended 31 December 2016.

The following MFRS and Interpretation issued by the MASB are not yet effective for adoption by the Group and are not expected to have any material impacts on the financial statements of the Group.

Amendments effective for financial periods beginning on or after 1 January 2018

- Amendments to MFRS 1 First-time Adoption of Reporting Standards (Annual Improvements 2014-2016 Cycle)
- Amendments to MFRS 2 Classification and Measurement of Share-based Payment Transactions
- MFRS 9 Financial Instruments
- MFRS 15 Revenue from Contracts with Customers
- Amendments to MFRS 128 Investments in Associates and Joint Ventures (Annual Improvements 2014-2016 Cycle)
- Amendments to MFRS 140 Transfers of Investment Property
- MFRS 10 Consolidated Financial Statements and MFRS 128 Investment in Associates and Joint Venture – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
- IC Interpretation 22 Foreign Currency Transactions and Advance Consideration

Amendments effective for financial periods beginning on or after 1 January 2019

- MFRS 16 Leases

A2. Auditors’ report on preceding annual financial statements

The audited financial statements of the Company and its subsidiaries for the FYE 31 December 2016 were not subjected to any qualification.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

A3. Seasonal or cyclical factors

The principal business operations of the Group were not significantly affected by seasonal or cyclical factors during the current quarter under review.

A4. Items of unusual nature and amount

There were no items affecting assets, liabilities, equity, net income or cash flows that were unusual because of their nature, size or incidence during the current quarter under review.

A5. Material changes in estimates

There were no material changes in estimates of amounts reported that will have a material effect in the current quarter under review.

A6. Issuances, cancellations, repurchase, resale and repayments of debt and equity securities

In the current quarter, a total of 110,080 Warrants 2014/2019 were exercised in the current quarter under review, total number of ordinary shares in issue increased to 482,318,347 as at 31 December 2017. Treasury share as at 31 December 2017 remained as 698,000.

A7. Dividend paid

A single tier interim dividend of RM0.003 per ordinary shares amounted to RM1,444,861 paid on 27 December 2017.

A8. Segmental information

Segmental revenue on the basis of geographical market is as follows:-

Geographical Market	Current Year-To-Date Ended 31 December 2017 RM'000	Corresponding Year-To-Date Ended 31 December 2016 RM'000
Asia other than Malaysia	5,127	6,988
Total export revenue	5,127	6,988
Malaysia	298,324	33,025
Total export and local revenue	303,451	40,013

For the current year-to-date, local revenue contributed about 98.31% of the Group's total revenue, mainly dependent on the trading of crude palm oil and palm kernel as well as sales of own produced Powder Fat products.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

A9. Valuation of property, plant and equipment

Revaluation of the Group's freehold lands and buildings has been brought forward without any amendments from the financial statement for FYE 31 December 2016.

A10. Capital commitments

Capital commitment authorised but not provided for in the interim financial statements under review as follows:

	31 December 2017	31 December 2016
	RM'000	RM'000
Property, Plant and Equipment		
- Contracted for	4,172	4,631

The outstanding balance as at 31 December 2017 mainly made up of commitments of the previous year.

A11. Material subsequent event after the Reporting Period

There were no material events subsequent to the end of the current quarter that have not been reflected in the financial statements, which are likely to substantially affect the current quarter results.

A12. Changes in the Composition of the Group

There were no change to the composition of the Group in the current quarter under review.

A13. Contingent Liabilities

Save for the following corporate guarantee, neither the Company nor its subsidiaries have any contingent liabilities at the end of the reporting period, which upon becoming enforceable, may have a material effect on the financial position of the Group.

The Company has placed a corporate guarantee amounting to RM17,131,000 in favour of Maybank Islamic Berhad in relation to Islamic banking facilities granted to Sunzen Corporation Sdn Bhd as follows:

Islamic Banking Facility	Corporate Guarantee	Facility Limit	Balance As At 31 December 2017
	RM'000	RM'000	RM'000
Bank overdraft	500	500	-
Trade line	6,000	6,000	-
Term loans	10,631	6,465	1,270
Total	17,131	12,965	1,270

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B. ADDITIONAL INFORMATION REQUIRED UNDER THE ACE LR

B1. Review of performance of the Company and its principal subsidiaries for the current quarter and financial year-to-date

	Current Quarter Ended 31 December 2017 RM'000	Corresponding Quarter Ended 31 December 2016 RM'000	Current Year-To-Date Ended 31 December 2017 RM'000	Corresponding Year-To-Date Ended 31 December 2016 RM'000
Revenue	103,091	14,043	303,451	40,013
Profit/(Loss) before tax	125	1,788	4,012	(455)

Group's revenue for the current quarter showed a significant increase compared to the corresponding quarter in the previous year due mainly to the trading of crude palm oil and palm kernel products. On year-to-date, the Group's revenue increased more than 7-fold to RM303 million compared to RM40 million previously.

Profit before tax for the current quarter was reported lower even though higher revenue achieved compared to the corresponding quarter due mainly to inventories and research and development cost written off, professional fee, unrealised foreign exchange loss in the current quarter and recognition of one-off gain in money market funds in the corresponding quarter in the previous year. However, based on year-to-date result, the Group posted a profit before tax of RM4.01 million in the current year compared to a loss before tax of approximately RM0.46 million a year ago. The improved year-to-date profit before tax was mainly attributed to profit contribution from trading of crude palm oil and palm kernel and lower sales incentives incurred in the current year.

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date

Revenue	Current Quarter Ended 31 December 2017 RM'000	Corresponding Quarter Ended 31 December 2016 RM'000	Current Year-To-Date Ended 31 December 2017 RM'000	Corresponding Year-To-Date Ended 31 December 2016 RM'000
Trading	95,086	6,381	274,281	14,281
Manufacturing	8,005	7,062	28,970	24,932
Project management	-	600	200	800
Total	103,091	14,043	303,451	40,013

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date (Cont'd)

Trading products revenue showed a sharp increase compared to the corresponding quarter due mainly to the trading of crude palm oil and palm kernel. Manufacturing products revenue also showed an increase relative to the corresponding quarter due mainly to the contribution from Powder Fat product. On year-to-date, trading products revenue contributed about 90.39% of the Group's revenue, mainly earned from the trading of crude palm oil and palm kernel.

B3. Profit/(Loss) before tax

Profit/(Loss) before tax is arrived at after (charging)/crediting:-

	Current Quarter Ended 31 December 2017 RM'000	Corresponding Quarter Ended 31 December 2016 RM'000	Current Year-To-Date Ended 31 December 2017 RM'000	Corresponding Year-To-Date Ended 31 December 2016 RM'000
Interest income	252	222	855	900
Interest expense	(20)	(49)	(95)	(199)
Depreciation	(272)	(279)	(989)	(959)
Inventories written off	(382)	(174)	(382)	(174)
Write back/(Write down) of inventories	332	552	449	(313)
Allowance for impairment loss on trade receivables	(6)	(5)	(6)	(5)
Gain/(Loss) on disposal of property, plant and equipment	-	14	-	(368)
(Loss)/Gain on foreign exchange:				
- realised	46	210	55	309
- unrealized	(165)	155	(204)	55

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B4. Material changes in the Current Quarter's results compared to the results of the immediate Preceding Quarter

	Current Quarter Ended 31 December 2017 RM'000	Preceding Quarter Ended 30 September 2017 RM'000	Variance	
			RM'000	%
Revenue	103,091	78,739	24,352	30.93
Profit before tax	125	1,403	(1,278)	(91.09)

Revenue for the current quarter showed 30.93% higher compared to the preceding quarter due mainly to the increase in the trading of crude palm oil and palm kernel products.

Profit before tax recorded lower compared to the preceding quarter due mainly to research and development cost written off and unrealised foreign exchange loss during the current quarter under review.

B5. Prospects

Sunzen is in the midst of expanding its present business spectrum through the proposed acquisition of 70% equity interest in Ecolite which is engaged in the manufacturing and trading of traditional Chinese medicines, herbal health foods and beverages.

B6. Profit forecast and profit guarantee

No profit forecast or profit guarantee has been issued by the Group in the current quarter.

B7. Income tax expense

	Current Quarter Ended 31 December 2017 RM'000	Corresponding Quarter Ended 31 December 2016 RM'000	Current Year-To-Date Ended 31 December 2017 RM'000	Corresponding Year-To-Date Ended 31 December 2016 RM'000
<u>Income tax expense:-</u>				
Current financial year	85	79	429	90
(Over)/Under-provision in the previous financial year	-	(29)	-	(29)
	<u>85</u>	<u>50</u>	<u>429</u>	<u>61</u>
<u>Deferred tax expense:-</u>				
Current financial year	(69)	(330)	(57)	(330)
Over-provision in the previous financial year	-	(126)	-	(126)
	<u>(69)</u>	<u>(456)</u>	<u>(57)</u>	<u>(456)</u>
Tax expense	16	(406)	372	(395)

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

B7. Income tax expense (Cont'd)

The Company's wholly-owned subsidiary, Sunzen LifeSciences Sdn. Bhd. is awarded with BioNexus status and granted a 100% tax exemption from the statutory income derived from the production of in-feed anti-bacterial products and supplements for animal health products for a period of 10 years spanning from 1 January 2010 to 31 December 2019.

B8. Status of Corporate Proposal

Proposed acquisition of 5,250,000 ordinary shares in Ecolite Biotech Manufacturing Sdn Bhd ("Ecolite"), representing 70% equity interest in Ecolite for a total purchase consideration of RM12,050,360

Subsequent to the announcements made on 1 July 2017, 7 November 2017 and 9 November 2017, the Company announced on 26 January 2018 that it reconsidered the proposal after issue that previously triggered the termination of the share sale agreement between the vendors and Sunzen has been resolved.

Share Issuance Scheme ("SIS"), with effective date 15 April 2016

Pursuant to the establishment of SIS of up to 30% of the Company's issued and paid-up capital (excluding treasury shares) for the eligible Directors and employees of Sunzen and its subsidiaries (excluding dormant subsidiaries), the Company has yet to finalise the details of the eligibility and allocation criteria as well as exercise of the SIS.

Warrants

As at 31 December 2017, the total number of Warrants exercised for warrants 2014/2019 and warrants 2016/2021 and the total number of unexercised warrants were as follows:

Warrants	Maturity date	Exercise price (RM)	Total number of warrants listed	Total number of warrants exercised	Total number of unexercised warrants
Warrants 2014/2019	14.04.2019	0.10	65,092,198	43,415,438	21,676,760
Warrants 2016/2021	25.02.2021	0.25	179,423,296	-	179,423,296

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B8. Status of Corporate Proposal (Cont'd)

Utilisation of Proceeds from Rights Issue of 179,423,296 ordinary shares

As at 31 December 2017, the status of utilisation of the gross proceeds of approximately RM44.855 million raised from the Rights Issue of shares at an exercise price of RM0.25 each is as follows:

Purpose	Proposed utilisation RM'000	Actual utilisation RM'000	Intended timeframe from the listing date* (Months)	Variation		Notes
				RM'000	%	
Purchase of machineries	17,000	7,758	6	-	-	(2)
Upgrade of building	2,800	1,696	6	-	-	(2)
Working capital	24,405	24,109	12	296	-	
Estimated listing expenses	650	946	0.5	(296)	-	(1)
Total	44,855	34,509				

Notes:

- * Listing date of Rights Shares on 4 March 2016.
- (1) Shortfall of the listing expenses incurred is adjusted from the working capital.
 - (2) The Company has announced on 5 September 2017 for a further extension of time for the utilisation of balance proceeds up to 4 September 2018 from 5 September 2017.

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

B9. Group borrowings and debt securities

The Group's borrowings as at 31 December 2017 were as follows:

	Secured RM'000	Unsecured RM'000	Total RM'000
<u>Short-term borrowings:-</u>			
Bills payable	-	-	-
Hire purchases	59	-	59
Term loans	370	-	370
	<u>429</u>	<u>-</u>	<u>429</u>
	Secured RM'000	Unsecured RM'000	Total RM'000
<u>Long-term borrowings:-</u>			
Hire purchases	150	-	150
Term loans	900	-	900
	<u>1,050</u>	<u>-</u>	<u>1,050</u>
Total	<u>1,479</u>	<u>-</u>	<u>1,479</u>

B10. Material Litigation

As at the date of this announcement, neither the Company nor any of its subsidiaries is engaged in any material litigation and arbitration either as plaintiff or defendant, which has a material effect on the financial position of the Company or its subsidiaries and the Directors are not aware of any proceedings pending or threatened or of any facts likely to give rise to any proceedings which might materially and adversely affect the financial position or business of the Company or its subsidiaries.

B11. Dividend declared or recommended

No dividend was declared for the current quarter under review.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B12. Earnings/(Loss) per share

Basic earnings/(loss) per share is calculated by dividing the Group's profit/(loss) after tax attributable to owners of the Company for the financial year over the weighted average number of ordinary shares in issue during the financial year excluding treasury shares.

	Current Quarter Ended 31 December 2017	Corresponding Quarter Ended 31 December 2016	Current Year-To-Date Ended 31 December 2017	Corresponding Year-To-Date Ended 31 December 2016
Group's profit/(loss) after tax attributable to owners of the Company (RM'000)	109	2,203	3,474	(130)
Weighted average number of ordinary shares in issue excluding treasury shares	480,177,826	448,614,591	480,177,826	448,614,591
Basic earnings/(loss) per share (sen)	0.02	0.49	0.72	(0.03)

Diluted earnings/(loss) per share is calculated by dividing the Group's profit/(loss) after tax attributable to owners of the Company for the financial year over the weighted average number of ordinary shares in issue during the financial year and adjustment for assumed exercise of Warrants of 534,662,947 (2016: 458,710,726).

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

B13. Disclosure of Realised and Unrealised Profits or Losses

The breakdown of the retained profits of the Group at the end of the reporting period is presented in accordance with the directive issued by Bursa Securities and prepared in accordance with Guidance on Special Matter No. 1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Securities Listing Requirements, as issued by the Malaysian Institute of Accountants.

	Current Year-To-Date Ended 31 December 2017 RM'000	Corresponding Year-To-Date Ended 31 December 2016 RM'000
Total retained profits of the Group:-		
- realised	20,878	17,901
- unrealised	(215)	709
 Group's retained profits as per consolidated financial statements	<hr/> 20,663	<hr/> 18,610

This quarterly report for the financial year ended 31 December 2017 has been reviewed and approved by the Board of Directors of Sunzen Biotech for release to Bursa Securities.

Date: 27 February 2018

